Predictive And Presymptomatic Testing Market Report 2026

Predictive And Presymptomatic Testing Market Overview

• Predictive And Presymptomatic Testing market size has reached to $5.78 billion in 2025 • Expected to grow to $9.31 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Rising Prevalence Of Genetic Disorders Fuels Growth In Predictive And Presymptomatic Testing Market • Market Trend: Advancements In Genetic Risk-Prediction Technologies To Support Preventive Healthcare • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Predictive And Presymptomatic Testing Market?

Predictive and presymptomatic testing are genetic tests designed to assess an individual's risk of developing a disease before any symptoms arise, particularly for inherited conditions. These tests help identify people at increased risk for specific genetic disorders, enabling early intervention and personalized care. The benefits include early diagnosis, tailored prevention, and informed lifestyle choices. The main test types of predictive and presymptomatic testing are predictive testing and presymptomatic testing. Predictive testing involves checking if someone has a genetic predisposition to develop a specific condition and disease in the future, even if they currently show no symptoms. The application includes cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and others and is used by various end users such as hospitals and clinics, diagnostic laboratories, research institutes, and others.

What Is The Predictive And Presymptomatic Testing Market Growth Forecast?

The predictive and presymptomatic testing market size is expected to see strong growth in the next few years. It will grow to $9.31 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising integration of AI in genomic analysis, expansion of population-scale screening programs, growing focus on preventive healthcare strategies, increasing regulatory support for genetic diagnostics. Major trends in the forecast period include growing adoption of preventive genetic screening, rising use of risk-based disease prediction models, expansion of genetic counseling services, increased focus on early disease detection, integration of genomic data in clinical decision-making.

What Is The Driver Of The Predictive And Presymptomatic Testing Market?

The rising prevalence of genetic disorders is expected to propel the growth of the predictive and presymptomatic testing market going forward. Genetic disorders are diseases caused by deoxyribonucleic acid (DNA) abnormalities, including gene mutations and chromosome changes, with conditions such as cystic fibrosis and Down syndrome as examples. The increasing prevalence of genetic disorders is attributed to factors such as advanced maternal age, environmental factors, and better diagnostic methods. Predictive and presymptomatic testing plays a crucial role in reducing the prevalence of genetic disorders by identifying individuals at risk before symptoms manifest. This proactive approach allows for early interventions or lifestyle adjustments that can help prevent or mitigate the severity of these conditions. For instance, in June 2023, according to the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials grew by 10% in quarter 3, 2023, the first quarterly increase since quarter 3, 2022. Therefore, the rising prevalence of genetic disorders is driving the predictive and presymptomatic testing industry.

Key Players In The Global Predictive And Presymptomatic Testing Market

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

Global Predictive And Presymptomatic Testing Market Trends and Insights

Major companies are operating in the predictive and presymptomatic testing market, focusing on developing innovative multi-gene testing solutions with enhanced genetic risk-scoring capabilities to enable earlier disease prediction and improve personalized prevention strategies. Polygenic-enabled panels combine sequencing of clinically relevant hereditary-risk genes with analysis of multiple common variants, allowing a more comprehensive and individualized assessment of future disease likelihood than traditional single-gene tests. For instance, in November 2025, Myriad Genetics Inc., a U.S.-based molecular diagnostics company, expanded its MyRisk Hereditary Cancer Test to include 63 clinically actionable genes across more than 11 cancer types. The expanded panel integrates next-generation sequencing with personalized lifetime and five-year cancer-risk estimates, enabling physicians to guide proactive clinical decision-making. The product enhances risk detection even in individuals without strong family histories and supports targeted surveillance, earlier screening initiation, and preventive care planning.

What Are Latest Mergers And Acquisitions In The Predictive And Presymptomatic Testing Market?

In July 2023, New Day Diagnostics, a US-based diagnostics and CRO services company, acquired substantially all assets of Epigenomics AG for up to US$12.05 million. Through this acquisition, New Day Diagnostics aims to enhance its early colorectal cancer screening capabilities by integrating Epigenomics’ blood-based Epi proColon test and associated biomarker technologies. Epigenomics AG is a Germany-based molecular diagnostics company that provides non-invasive colorectal cancer screening through its Epi proColon blood test.

What Defines the Predictive And Presymptomatic Testing Market?

The predictive and presymptomatic testing market consists of revenues earned by entities by providing services such as genetic testing, risk assessment, early disease detection, biomarker testing, and predictive modelling. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive and presymptomatic testing market also includes sales of carrier screening tests, genetic tests, diagnostic tools, prenatal testing kits, and Alzheimer's disease biomarkers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Predictive And Presymptomatic Testing Market Report 2026?

The predictive and presymptomatic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the predictive and presymptomatic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.